7th Jun 2021 14:35
Renalytix AI PLC - Cardiff, Wales-based clinical diagnostics for kidney disease - Notes series of senior management hires in the US to improve its commercialisation strategy.
"The combined background and experience of the new leadership team is expected to drive adoption of the KidneyIntelX testing and care model implementation in early stage diabetic kidney disease populations," company says.
It adds: "Renalytix expects to continue expanding its sales, marketing, and implementation teams with expected KidneyIntelX roll-out beginning in the VA Medical Health System in the 2nd half of 2021, and as the company positions for a broader national expansion beginning in fiscal 2022 in line with expectations for a national Medicare insurance coverage determination later this year."
Appoints Missy Martin-Kemp as vice president of sales, Eastern US, Christine Loftsgaarden as vice president of commercial partnerships, Stacey Molinari as director of commercial partnerships, Jon Wisson as senior manager, government access and Andria Parks-Herrera as vice president of marketing.
President Tom McLain says: "The Renalytix technology and market opportunity are attracting a very high caliber of commercial talent. This group brings first-hand professional success launching and commercialising innovative solutions in both private and government driven healthcare delivery models. Their contributions will accelerate our expansion into new health systems which in turn will drive adoption and revenue growth in 2022 and 2023."
Current stock price: 1,140.00 pence, down 3.0% on Monday
Year-to-date change: more than doubled from 487.50p
By Paul McGowan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc